Business Context and Reporting Period
Company: Oncolytics Biotech Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 6, 2026
Reporting Period: The filing addresses events occurring on July 6, 2026, related to a corporate restructuring.
Key Financial Metrics
This filing does not contain specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity figures. The document focuses exclusively on a change in the registrant's certifying accountant.
Material Changes
- Accountant Change: Due to corporate restructuring, the Audit Committee voted to disengage Ernst & Young LLP (EY) and engage Baker Tilly US, LLP as the independent registered public accounting firm for the 2026 fiscal year.
- Historical Audit Status: EY's reports for fiscal years ended December 31, 2025, and December 31, 2024, did not contain adverse opinions, disclaimers, or qualifications regarding uncertainty, audit scope, or accounting principles.
- Going Concern: EY's reports for the aforementioned periods included an explanatory paragraph regarding the Company's ability to continue as a going concern.
- Disagreements: There were no disagreements with EY on accounting principles, practices, or auditing scope during the relevant periods.
Guidance, Outlook, and Risks
Management Commentary: The change in auditors is attributed to the Company's corporate restructuring. The engagement of Baker Tilly is subject to the completion of client acceptance procedures.
Risks and Contingencies: The filing notes the historical presence of a going concern explanatory paragraph in prior audit reports. No new risks or contingencies are detailed in this specific document beyond the transition of audit services.
Consultations: The Company did not consult with Baker Tilly regarding accounting principles, audit opinions, or reportable events prior to engagement.
Investor Verification Checklist
- Verify the status of the "corporate restructuring" cited as the reason for the auditor change.
- Review the attached Exhibit 16.1 (Letter from Ernst & Young LLP) to confirm their agreement with the Company's statements.
- Monitor the Company's liquidity and capital resources given the historical "going concern" qualification noted in prior years.
- Confirm the completion of Baker Tilly's client acceptance procedures to ensure the 2026 audit engagement is finalized.